Balazs Halmos – författare
Visar alla böcker från författaren Balazs Halmos. Handla med fri frakt och snabb leverans.
6 produkter
Targeting Oncogenic Driver Mutations in Lung Cancer
Av Balazs Halmos, Shirish Gadgeel m. fl.
E-bok, 2023
303 kr
Lägg i varukorg
The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant …
Targeting Oncogenic Driver Mutations in Lung Cancer
Av Balazs Halmos, Shirish Gadgeel m. fl.
E-bok, 2023
303 kr
Lägg i varukorg
The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant …
Targeting Oncogenic Driver Mutations in Lung Cancer
Av Matthew Lee, Fawzi Abu Rous m. fl.
Häftad, 2023
317 kr
Lägg i varukorg
The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant …
EGFR-Directed Therapy in Lung Cancer
Av Balazs Halmos, Susumu Kobayashi m. fl.
E-bok, 2023
303 kr
Lägg i varukorg
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from …
EGFR-Directed Therapy in Lung Cancer
Av So Yeon Kim, Daniel B. Costa m. fl.
Häftad, 2023
317 kr
Lägg i varukorg
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from …
EGFR-Directed Therapy in Lung Cancer
Av Balazs Halmos, Susumu Kobayashi m. fl.
E-bok, 2023
303 kr
Lägg i varukorg
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is a clinically important driver alteration affecting approximately one-third of lung cancer patients. Treatments for EGFR-exon 19 deletion and exon 21 L858R NSCLC have evolved over the last decade from …